These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1850388)

  • 1. Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive.
    Lagadec PF; Saraya KA; Balkwill FR
    Int J Cancer; 1991 May; 48(2):311-7. PubMed ID: 1850388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M; Spatafora M; Melodia A; Pace E; Gjomarkaj M; Merendino AM; Bonsignore G
    Eur Respir J; 1996 Sep; 9(9):1831-8. PubMed ID: 8880099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
    Yoneda K; Osaki T; Yamamoto T; Ueta E
    Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
    Brooks B; Chapman K; Lawry J; Meager A; Rees RC
    Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
    Swisher SG; Economou JS; Holmes EC; Golub SH
    Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
    Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
    Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
    Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
    Azuma A
    Nihon Ika Daigaku Zasshi; 1991 Dec; 58(6):663-72. PubMed ID: 1663120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived, cytostatic factor.
    Tachibana I; Watanabe M; Tanio Y; Hayashi S; Hosoe S; Saito S; Matsunashi M; Osaki T; Shigedo Y; Masuno T
    Cancer Res; 1992 Jun; 52(12):3310-6. PubMed ID: 1350752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells.
    Sugiura H; Ishikura H; Omi M; Kaji M; Iwai K; Kishimoto T; Takahashi T; Kimura C; Kato H; Yoshiki T
    Pathol Int; 1994 Sep; 44(9):688-96. PubMed ID: 7804431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.
    Tanio Y; Watanabe M; Osaki T; Tachibana I; Kawase I; Kuritani T; Saito S; Masuno T; Kodama N; Furuse K
    Jpn J Cancer Res; 1992 Jul; 83(7):736-45. PubMed ID: 1325431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.